View Press Releases

Saama Appoints Andrew J. (A.J.) Mills as Company’s Chief Commercial Officer

August 14, 2022

CAMPBELL, CA – (August 15, 2022) – Saama Technologies, LLC. (“Saama”) today announced that life science industry sales and marketing expert Andrew J. (AJ) Mills has been appointed as the company’s Chief Commercial Officer, effective August 15, 2022. AJ is responsible for leading all global sales and marketing activities at Saama to drive revenue and aggressive business growth. AJ will report to Saama CEO Vivek Sharma.


AJ is a strategic sales and marketing executive with nearly two decades of drug development and clinical trials analytics experience, as well as a proven ability to successfully build and guide sales teams to exceed targets. He joins Saama from clinical trial data management company Clario (formally ERT/BioClinica), where he served as Global Vice President with responsibility for all aspects of sales and commercial market strategy for Clario’s eCOA, Precision Motion & Clario One (platform, data/analytics, connected devices) divisions. AJ also spent four years in various sales positions at ICON Clinical Research, most recently as Executive Director, Specialty Sales – Site and Patient Solutions, where he was focused on reducing Patient and Site burden through the use of Technology, Decentralized Trial Solutions, and ICON’s Site Management Organization (Accellacare).


“AJ is a dynamic, strategic, and exceptionally driven commercial executive who is the perfect choice to lead Saama’s Global Sales function in its next phase of growth,” said Vivek. “AJ’s expertise, passion, and ability to inspire those around him make him an excellent addition to our Executive Leadership Team and will further drive Saama’s mission of enabling life sciences to bring safe and effective treatments to patients sooner.” 


“I am incredibly excited and energized to lead Saama’s commercial organization. I have been in the Clinical Trials industry for nearly 20 years, and the solution Saama brings is truly revolutionary in its ability to accelerate trials,” said AJ. “It is an exciting time to be part of Saama’s journey, and I look forward to working in partnership with Vivek and the rest of the Executive Leadership Team to continue improving the clinical development paradigm with Saama’s purpose-built, AI-based clinical insights and automation platforms that are leading the exciting new ClinTech category.”


AJ holds a Bachelor of Science degree in Zoology from the University of Reading in the UK and studied Strategic Sales Management at the University of Chicago Graduate School of Business.


About Saama Technologies, LLC.

Saama is the life science industry leader of ClinTech, the new category of purpose-built, AI-based clinical insights and automation platforms empowering faster, safer clinical development and regulatory programs. Over 50 biotech companies–including many top 20 pharmaceutical companies–use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate over 1,500 studies, including the clinical trial for the world's first COVID-19 vaccine. LSAC’s rich applications facilitate unprecedented, authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring treatments to patients sooner. Discover more: Follow @SaamaTechInc on Twitter.




Media Contact

Saama Technologies

Pat Fiaschetti